SCHEMBL5928941

SCHEMBL5928941

CCCCn1c(-c2c(C)cccc2C)nc(Cl)c1CN1CCCCC1c1ccc(OC)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ OPRK1 P41145 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ OPRM1 P35372 1/20 0.38
▸ DRD2 P14416 2/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ IL33 O95760 2/20 0.35
▸ CFB P00751 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5929301 1.00 KDM4E (0.39) KDM4EALDH1A1OPRK1MAPTRAB9A
SCHEMBL5929052 1.00 KDM4E (0.39) KDM4EALDH1A1OPRK1MAPTRAB9A
SCHEMBL5929216 0.92 OPRK1 (0.39) KDM4EALDH1A1OPRK1MAPTRAB9A
SCHEMBL5929251 0.90 CFB (0.40) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL5929025 0.89 CFB (0.37) KDM4EALDH1A1MAPTRAB9AMEN1
SCHEMBL5928942 0.86 CFB (0.37) KDM4EALDH1A1OPRK1OPRM1DRD2
SCHEMBL5929255 0.85 KMT2A (0.38) KDM4EALDH1A1MAPTDRD2DRD3
SCHEMBL5929023 0.84 CFB (0.43) OPRK1OPRM1CYP3A4CYP2D6KCNH2
SCHEMBL5929089 0.84 CFB (0.43) KDM4EALDH1A1OPRK1MAPTRAB9A
SCHEMBL5929015 0.84 CFB (0.50) KDM4EALDH1A1OPRK1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060154917-A1 Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators NEUROGEN CORPORATION (US) 2006-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154917-A1 Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators C5AR1, C5AR2, C3AR1 KDM4E 1762/4885ALDH1A1 3884/4885OPRK1 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback